Home › Funds › GSK plc › VIR

GSK plc position in VIR

VIR BIOTECHNOLOGY INC · Health Care

GSK plc reported holding 8,550,954 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q3 2026 13F filing — a position valued at US$95.6M, representing 19.23% of its reported portfolio and ranking #2 among its reported holdings. GSK plc has disclosed VIR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)8.55M sh
Reported value held$95.60M
Portfolio Weight19.23%
First reportedQ4 2025
Last changeHold
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How GSK plc's VIR position evolved

GSK plc first disclosed a stake in VIR in Q4 2025 at 8,550,954 shares (US$51.6M). The position peaked in Q3 2026 at 8,550,954 shares, worth US$95.6M. Across 4 filings, GSK plc held the position steady without any share-count change. The most recent filing (Q3 2026) shows 8,550,954 shares valued at US$95.6M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 8.55M $51.56M New
Q1 2026 8.55M $76.62M Hold
Q2 2026 8.55M $87.13M Hold
Q3 2026 8.55M $95.60M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VIR and 13F data

VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 49 other funds we track also report a position in VIR — the largest reported positions include ARCH Venture Management, LLC (US$129.4M), SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), ADAR1 Capital Management, LLC (US$25.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VIR

All VIR fund holders →

FAQ

How long has GSK plc held VIR?

GSK plc has disclosed VIR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is GSK plc's current position in VIR?

As of Q3 2026, GSK plc holds 8.55M shares of VIR (VIR BIOTECHNOLOGY INC), valued at $95.60M, representing 19.23% of its reported portfolio and ranking #2.

Has GSK plc been buying or selling VIR?

In the latest 13F filing (Q3 2026), GSK plc held unchanged its position in VIR. The position peaked in Q3 2026 at 8.55M shares.

Which other funds hold VIR?

Other major institutional holders of VIR include ARCH Venture Management, LLC, SB INVESTMENT ADVISERS (UK) LTD, ADAR1 Capital Management, LLC, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.